Navidea biopharmaceuticals, inc. (NAVB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-10,948

-16,114

74,945

-14,309

-27,563

-35,726

-42,699

-

-

-

-

Net loss

-

-

-

-

-

-

-

-29,157

5,612

-49,964

-39,605

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

103

120

232

496

562

487

-

198

175

215

202

Depreciation and amortization of property and equipment

-

-

-

-

-

-

400

-

-

-

-

Amortization of license agreements, patents and trademarks

41

29

22

5

8

12

3

1

1

7

131

Loss on disposal and abandonment of patents and equipment

-60

-

-807

-136

-33

-31

-1

-2

-18

-7

-18

Compounded interest on long term debt

-

153

-

-

-

-

-

-

-

-

-

Gain on forgiveness of accounts payable

-

-

212

85

0

0

-

-

-

-

-

Change in inventory reserve

-

-

-

43

143

539

-

-

-

-

-

Change in inventory reserve

-

-

-

-

-

-

-

0

-

-

-

Amortization of debt discount and issuance costs

-

-

-

77

492

844

765

-

-

-

-

Debt discount and issuance costs written off

-

-

-

1,955

0

0

-

-

-

-

-

Prepayment premium and debt collection fees related to long term debt

-

-

-

2,923

0

0

-

-

-

-

-

Compounded interest on long term debt

-

-

265

1,561

2,048

0

-

-

-

-

-

Amortization of debt discount and debt offering costs

-

-

-

-

-

-

-

544

3

16

428

Issuance of common stock in payment of interest and dividends

-

-

-

-

-

-

-

-

-

476

791

Stock compensation expense

232

306

394

277

2,368

1,634

2,908

2,304

3,592

597

445

Equity in loss of R-NAV, LLC

-

-

-

-15

-305

-523

-

0

-

-

-

Loss on disposal of investment in R-NAV, LLC

-

-

-

-39

0

0

-

-

-

-

-

Change in fair value of financial instruments

-

-

153

2,858

-614

-1,342

-112

-

-

-

-

Change in fair value of financial instruments

-

-

153

2,858

-614

-1,342

-

-

-

-

-

Change in fair value of financial instruments

-

-

-

-

-

-

-

32

-952

-1,336

-18,132

Loss on extinguishment of debt

-

-5,291

-4,201

0

-2,440

-2,610

-1,372

0

0

-41,717

-16,240

Value of stock issued to directors

-

-

10

66

172

-

-

-

-

-

-

Value of stock issued in payment of employee bonuses

-

616

369

0

0

-

-

-

-

-

-

Value of stock issued to 401(k) plan for employer matching contributions

19

35

53

120

117

100

66

-

-

-

-

Issued warrants in connection with Asset Sale

-

-

3,337

0

0

0

166

-

-

-

-

Extension of warrant expiration date

-

-

-

0

-149

0

-

-

-

-

-

Value of restricted stock issued to directors

-

-

-

-

-

89

-

-

-

-

-

Value of stock issued in payment of services

14

-

-

0

256

-

-

1,146

-

279

-

Other

-

-

-

15

63

38

-4

-

-

-

-

Gain on sale of GDS Business, before income tax

-

-

-

-

-

-

-

-

26,173

0

-

Issuance of common stock for payment of milestone and sublicense fees

-

-

-

-

-

-

-

-

0

0

-

Impairment loss on Cardiosonix

-

-

-

-

-

-

-

-

-

-

-1,713

Other

-

-

-

-

-

-

-

61

61

40

33

Changes in operating assets and liabilities:
Accounts and other receivables

-

-

-

-

-

-

1,042

-

-

-

-

Accounts and other receivables

68

-12,926

11,145

-1,882

2,808

-334

-

-6

219

707

-296

Inventory

-

-

-1,470

861

-135

-761

1,934

-524

53

381

653

Prepaid expenses, right-of-use lease assets, and other assets

-696

-805

934

-187

-263

476

-84

385

40

-39

-105

Accounts payable

687

-430

-6,017

5,441

290

-944

1,003

736

-538

759

38

Accrued, lease and other liabilities

-195

548

-6,248

5,351

-282

-1,250

3,176

125

487

157

121

Deferred revenue

2

-15

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-2,315

1,104

1,237

0

-

-

109

232

77

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-35,612

-

-

-

-

Net cash used in operating activities

-9,354

4,275

59,083

3,556

-19,076

-29,126

-

-23,923

-16,010

-5,169

-1,482

Cash flows from investing activities:
Purchases of available-for-sale securities

-

600

2,200

0

0

-

-

-

-

-

-

Proceeds from sales of available-for-sale securities

400

200

-

-

-

-

-

-

-

-

-

Maturities of available-for-sale securities

400

1,400

400

0

0

-

-

-

-

-

494

(Payments for purchases) proceeds from disposal of equipment

27

-46

-

-

-

-

-

-

-

-

-

Patent and trademark costs

56

0

-

-

-

-

-

-

-

-

-

Purchases of equipment

-

-

33

1

39

1,114

1,239

663

183

366

96

Proceeds from sales of equipment

-

-

-

-45

-38

0

-

-

-

-

-

Proceeds from sales of equipment

-

-

-

-

-

-

-

-

1

0

0

Proceeds from sale of GDS Business, net

-

-

-

-

-

-

-

-

30,159

0

-

Payments of costs to sell GDS Business

-

-

-

-

-

-

-

-

2,765

0

-

Patent and trademark costs

-

-

-

0

27

77

52

8

52

32

71

Investment in R-NAV, LLC

-

-

-

-

-

333

-

-

-

-

-

Payments on disposal of investment in R-NAV, LLC

-

-

-

110

0

0

-

-

-

-

-

Proceeds from disposal of investment in R-NAV, LLC

-

-

-

27

0

0

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-1,292

-

-

-

-

Investment in R-NAV, LLC

-

-

-

-

-

-

-

0

-

-

-

Net cash (used in) provided by investing activities

770

953

-1,833

-39

-27

-1,524

-

-671

27,158

-398

326

Cash flows from financing activities:
Proceeds from issuance of common stock

7,086

3,000

72

13

65

87

41,303

2,724

7,198

7,092

3,641

Proceeds from issuance of MT Preferred Stock and warrants

-

-

-

0

500

0

-

-

-

-

-

Payment of common stock issuance costs

572

-

-

0

12

0

-

-

-

-

219

Payment of common stock issuance costs

-

-

-

-

-

-

1,752

0

0

478

-

Payment for common stock repurchased from executives

-

-

-

-

-

-

-

100

0

0

-

Payment of tax withholdings related to stock-based compensation

-

-

-

0

23

130

659

8

2,762

133

24

Payment of preferred stock dividends

-

-

-

-

-

-

-

100

100

111

-

Proceeds from notes payable

-

-

-

0

54,500

30,000

29,000

4,000

7,000

0

-

Payment of debt-related costs

-

-

-

-

-

-

1,177

153

189

0

20

Payment of debt-related costs

-

7,153

1,314

3,923

3,902

1,763

-

-

-

-

-

Principal payments on notes payable

359

395

59,753

231

30,333

25,000

5,982

1,285

62

8

137

Restricted cash held for payment against debt

-

-

-

-5,001

0

0

-

-

-

-

-

Payments under capital leases

-

-

-

2

2

2

7

5

8

11

9

Net cash used in financing activities

-

-

-

-

-

-

60,724

-

-

-

-

Net cash provided by (used in) financing activities

6,155

-4,548

-60,995

-9,144

20,791

3,191

-

5,069

11,075

6,349

3,229

Net decrease in cash and cash equivalents

-2,428

680

-3,745

-

-

-

-

-

-

-

-

Net increase (decrease) in cash

-

-

-

-5,626

1,687

-27,460

-

-

-

-

2,074

Net (decrease) increase in cash

-

-

-

-

-

-

23,820

-19,525

22,223

780

-